Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

Cancer Science

Volumn 107, Issue 7, 2016, Pages 1039-1046

  Ogitani, Yusuke ^a   Hagihara, Katsunobu ^a   Oitate, Masataka ^a   Naito, Hiroyuki ^a   Agatsuma, Toshinori ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Antibody drug conjugate; bystander killing; HER2; T DM; topoisomerase I inhibitor

Indexed keywords

ANTIBODY CONJUGATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EXATECAN; LUCIFERASE; TRASTUZUMAB EMTANSINE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CELL GROWTH; CELL MEMBRANE PERMEABILITY; COCULTURE; CONJUGATE; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 84978852658     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12966     Document Type: Article

References (27)

1. Bross PF, Beitz J, Chen G et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 1490–6.
2. Petersdorf SH, Kopecky KJ, Slovak M et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013; 121: 4854–60.
3. Gopal AK, Ramchandren R, O'Connor OA et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 2012; 120: 560–8.
4. Younes A, Gopal AK, Smith SE et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30: 2183–9.
5. Ogura M, Tobinai K, Hatake K et al. Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci 2014; 105: 840–6.
6. Burris HA 3rd, Rugo HS, Vukelja SJ et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011; 29: 398–405.
7. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783–91.
8. Krop IE, Kim SB, Gonzalez-Martin A et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 689–99.
9. Hamilton GS. Antibody-drug conjugates for cancer therapy: the technological and regulatory challenges of developing drug-biologic hybrids. Biologicals 2015; 43: 318–32.
10. Hinrichs MJ, Dixit R. Antibody drug conjugates: nonclinical safety considerations. AAPS J 2015; 17: 1055–64.
11. Sapra P, Shor B. Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol Ther 2013; 138: 452–69.
12. Ogitani Y, Aida T, Hagihara K et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising anti-tumor efficacy with differentiation from T-DM1. Clin Cancer Res 2016; doi: 10.1158/1078-0432.CCR-15-2822.
13. Kovtun YV, Audette CA, Ye Y et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006; 66: 3214–21.
14. Golfier S, Kopitz C, Kahnert A et al. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther 2014; 13: 1537–48.
15. van der Lee MM, Groothuis PG, Ubink R et al. The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers. Mol Cancer Ther 2015; 14: 692–703.
16. Li JY, Perry SR, Muniz-Medina V et al. A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell 2016; 29: 117–29.
17. Nakada T, Masuda T, Naito H et al. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads. Bioorg Med Chem Lett 2016; 26: 1542–5.
18. Shiose Y, Ochi Y, Kuga H, Yamashita F, Hashida M. Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors. Biol Pharm Bull 2007; 30: 2365–70.
19. Niedergethmann M, Wostbrock B, Sturm JW, Willeke F, Post S, Hildenbrand R. Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma. Pancreas 2004; 29: 204–11.
20. Aggarwal N, Sloane BF. Cathepsin B: multiple roles in cancer. Proteomics Clin Appl 2014; 8: 427–37.
21. Sun X, Widdison W, Mayo M et al. Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug Chem 2011; 22: 728–35.
22. Erickson HK, Lewis Phillips GD, Leipold DD et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther 2012; 11: 1133–42.
23. Kovtun YV, Audette CA, Mayo MF et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 2010; 70: 2528–37.
24. Lewis Phillips GD, Li G, Dugger DL et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68: 9280–90.
25. Francisco JA, Cerveny CG, Meyer DL et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003; 102: 1458–65.
26. Lee HE, Park KU, Yoo SB et al. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer 2013; 49: 1448–57.
27. Bethune GC, Mullen JB, Chang MC. Detecting intratumoral heterogeneity in routine breast-HER2 testing: low yield of testing multiple blocks. Ann Diagn Pathol 2015; 19: 385–90.